[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebrovascular-accident\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebrovascular-accident":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,48,76,103,137,165,194,223,261,299,321,341,370,404,428,458],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100058931","natural-history-of-stroke-cause-and-development-100058931",false,"NCT00009243","Natural History of Stroke: Cause and Development","Evaluation, Pathogenesis, and Treatment of Patients With or at Risk for Cerebrovascular Disease (A Natural History\u002FDisease Pathogenesis Protocol)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Aged \\>=18\n2. Presented to participating study site (ED, ICU, or inpatient unit) with or at risk of acute stroke, TIA, or other disturbances of cerebrovascular circulation\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Subjects with contraindication to MRI scanning will be excluded from any testing which involves the use of MRI. The contraindications include subjects with the following devices or conditions:\n\n   * Central nervous system aneurysm clips\n   * Implanted neural stimulator\n   * Implanted cardiac pacemaker or defibrillator\n   * Cochlear implant\n   * Ocular foreign body (e.g. metal shavings)\n   * Insulin pump\n   * Metal shrapnel or bullet\n   * Any implanted device that is incompatible with MRI\n\n   Subjects with a condition precluding entry in the scanner (e.g. morbid obesity, Claustrophobia, etc.) will not be included in the MRI portion of this study.\n2. Pregnancy","ALL","18 Years","120 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies.\n\nPatients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland.\n\nThe study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following:\n\n* Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests.\n* Electrocardiogram (EKG) (heart tracing)-electrodes placed on the chest wall detect the heartbeat and heart rhythm.\n* Computed tomography (CT) scan of the head-specialized X-rays are used to obtain images of the brain.\n* Magnetic resonance imaging (MRI) of the brain-a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels.\n* Transcranial Doppler (TCD)-sound waves are used to image the arteries of the brain and neck.\n* Echocardiogram-sound waves are used to image the heart and evaluate heart function.\n\nPatients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and\u002For 12 months, when some of these tests may be repeated to assess changes over time",[25,26,27,28,29],"Brain Disease","Ischemic Attack, Transient","Cerebrovascular Accident","Cerebrovascular Disorder","Vascular Diseases",[31,32,33,34,35,36],"Stroke","Natural History","MRI (Magnetic Resonance Imaging)","Magnetic Resonance Imaging","Acute Stroke","TIA","RECRUITING","2026-06-13",{"date":40,"type":41},"2026-06-16","ACTUAL",{"date":43,"type":41},"2001-01-26",{"name":45,"class":46},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100532393","neurofeedback-eeg-rehabilitation-protocol-on-motor-recovery-in-the-subacute-phase-post-stroke-custom-nf-stroke-100532393","NCT06212219","Neurofeedback-EEG Rehabilitation Protocol on Motor Recovery in the Subacute Phase Post-stroke (CUSTOM-NF-STROKE)","Impact of Personalization of a Neurofeedback-EEG Rehabilitation Protocol on Motor Recovery in the Subacute Phase Post-stroke (CUSTOM-NF-STROKE)","Inclusion Criteria:\n\n* Man, woman, over 18 years old\n* Motor deficit of the upper limb type of hemiplegia, secondary to a hemorrhagic or ischemic stroke authenticated by brain imaging (MRI or CT)\n* Post-stroke patients in the subacute phase, between 15 days and 6 months after the stroke\n* Correct or corrected vision allowing reading at a distance of 0 to 2m\n* Ability to maintain a seated position for 1 hour\n* Patient affiliated to a social security scheme or beneficiary of such a scheme\n* Informed patient having signed consent\n\nExclusion Criteria:\n\n* Minors (age \\\u003C 18 years)\n* Phasic disorder limiting comprehension corresponding to a Boston Diagnostic Aphasia Examination (BDAE) score \\\u003C 4\n* Attentional disorder not allowing sufficient attention to be maintained for 1 hour\n* History of known stroke with motor sequelae.\n* Known peripheral neurological pathology affecting the paretic upper limb.\n* Other known central neurological pathology\n* Factors hindering EEG acquisition (scalp pathology, abnormal cervico-cephalic movements, cranial metal implants)\n* Unstabilized epilepsy\n* Refusal to participate in the study\n* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision\n* Pregnant, parturient, or breastfeeding patient","99 Years",{"count":57,"type":21},44,"INTERVENTIONAL",[60],"NA","Neurofeedback (NF) is a procedure for providing direct sensory feedback (in the form of visual, auditory or tactile stimulation) to a patient about their brain activity when performing a cognitive or motor task. This NF aims to allow the patient to become aware of this brain activity and thus learn to modulate it voluntarily in order to improve the performance obtained on the task.\n\nThe aim of the study is to compare a \"standard NF\" procedure to a \"personalized NF\" procedure designed to optimize the level of patient acceptability based on the results obtained through these questionnaires.",[27],[64],"Neurofeedback","2026-05-28",{"date":67,"type":41},"2026-05-29",{"date":69,"type":41},"2024-01-08",{"date":71,"type":21},"2027-12-31",{"name":73,"class":74},"University Hospital, Toulouse","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":75},"100488777","nomad-p-kafo-study-100488777","NCT05644522","Nomad P-KAFO Study","Power Forward Study: A Cross-Sector, Multisite Clinical Trial of a Powered Knee-Ankle-Foot Orthosis","Inclusion Criteria:\n\n* Regular and compliant use of a unilateral or bilateral KAFO or SCO or other passive KAFOs for impairment due to neurological or neuromuscular disease, orthopedic disease, or trauma\n* Cognitive ability to understand and follow the study protocol; willingness to provide informed consent\n* Willing to wear and charge an activity monitor for three-months home trials.\n\nExclusion Criteria:\n\n* Flexion contracture in the knee and\u002For hip joint in excess of 15 degrees\n* Non-correctable knee varus\u002Fvalgus in excess of 15 degrees\n* Severe spasticity\n* Inability to stabilize the trunk with or without assistive devices (crutches, canes, etc.)","89 Years",{"count":85,"type":21},36,[60],"The goal of this clinical trial is to evaluate the impact of using the Nomad powered KAFO in people who have had a musculoskeletal or neurological injury that has affected their ability to walk. The main questions it aims to answer are to quantify the effectiveness of the Nomad in improving mobility, balance, frequency of falls, and quality of life in individuals with lower-extremity impairments compared to their own brace, over three months of daily home and community use.\n\nParticipants will:\n\n* Wear a sensor that records everyday activities and mobility.\n* Perform measures of mobility and different activities of participation using their own brace.\n* Perform measures of mobility and different activities of participation using the Nomad powered KAFO",[27,89,90,91,92,93],"Post-polio Syndrome","Spinal Cord Injuries","Multiple Sclerosis","Muscular Dystrophy","Paralysis","2026-05-07",{"date":96,"type":41},"2026-05-11",{"date":98,"type":41},"2024-03-01",{"date":100,"type":21},"2027-12",{"name":102,"class":74},"Shirley Ryan AbilityLab",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":58,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":75},"100489348","cardiac-rehabilitation-of-stroke-survivors-srp-cross-100489348","NCT05651945","Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)","Stroke Recovery Program-Cardiac Rehabilitation of Stroke Survivors","SRP-CROSS","Inclusion Criteria:\n\n* 18 years or older\n* Stroke diagnosis (ischemic or hemorrhagic) \u002F radiologic evidence of acute stroke\n* Medically cleared by a cardiologist for participation in the cardiac rehabilitation program with no contraindications to cardiac rehabilitation per American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) guidelines\n* Ability to transfer on\u002Foff the recumbent bike with or without an assistive device safely, with or without assistance from another person\n* Ability to follow simple commands and communicate pain or distress\n* Admission to an Inpatient Rehabilitation Facility post-stroke\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Presence of subarachnoid hemorrhage, intracranial aneurysm, intracranial hemangioma, or arteriovenous malformation\n* Medical disorders that preclude participation in the study as determined by the Principal Investigator.\n* Inability to have baseline assessment within 60 days post-stroke diagnosis\n* Patient considered unable to comply with study requirements\n* Known terminal illness with life expectancy less than 1 year\n* Compliant diagnosis eligible for traditional cardiac rehabilitation covered by insurance\n* Unable to understand\u002Fspeak English",{"count":112,"type":21},150,[60],"This study examines the effectiveness of the cardiac rehabilitation program for stroke patients. The study will examine if patients with stroke, who receive cardiac rehabilitation in addition to their standard of care treatments, demonstrate improved recovery of function. It will also examine if these patients have reduced hospital readmission, reduced rate of recurrent stroke, and mortality.",[31,27],[117,118,119,120,121,122,123,124,125,126,127],"cardiac rehabilitation","stroke","stroke rehabilitation","stroke recovery","exercise","cardiovascular disease","cardiovascular function","cognitive function","physical function","neurorehabilitation","transition of care post stroke","2026-02-03",{"date":130,"type":41},"2026-02-05",{"date":132,"type":41},"2023-01-20",{"date":134,"type":21},"2031-01-20",{"name":136,"class":74},"Hackensack Meridian Health",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":148,"studyType":22,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":75},"100556185","cardio-renal-registry-100556185","NCT06521801","Cardio-Renal Registry","Barts Health Cardio-Renal Registry","BHCRR","Informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Nephrology team.\n\nInclusion Criteria:\n\n1. Both male and female patients ≥16 years of age will be included\n2. All patients will be reviewed by the Nephrology team a the RLH with renal disease.\n\nExclusion Criteria:\n\n1\\. Patients \\\u003C16 years will not be included in this study.","16 Years",{"count":147,"type":21},60000,"12 Weeks","Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \\\u003C60 mL\u002Fmin\u002F1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the \"treatment risk paradox,\" has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population.\n\nThis data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.",[151,152,153,27,154,155],"End Stage Renal Disease","Cardio-Renal Syndrome","Myocardial Infarction","Percutaneous Coronary Intervention","Dialysis","2026-01-05",{"date":158,"type":41},"2026-01-07",{"date":160,"type":41},"2024-08-01",{"date":162,"type":21},"2030-06-01",{"name":164,"class":74},"Queen Mary University of London",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":58,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100613872","effects-of-tvns-and-mcimt-in-chronic-stroke-100613872","NCT07272239","Effects of tVNS and mCIMT in Chronic Stroke","Combined Effects of Transcutaneous Vagus Nerve Stimulation and Modified Constraint Induced Movement Therapy on Upper Extremity Function, Cognition and Quality of Life in Individual With Chronic Stroke","Inclusion Criteria:\n\n* Both male and female patients are included in the study.\n* Left sided ischemic stroke patients.\n* Patients with chronic, moderate-severe upper limb hemiparesis (\\>6 months-2 years)\n* Stable participants having a stroke severity score \\> 6 on National Institute of Health Stroke Scale (NIHSS).\n* Montreal Cognitive Assessment (MoCA) score ≥26.\n\nExclusion Criteria:\n\n* Participants who show the symptoms of global or receptive aphasia.\n* Participants who have a history of significant neurological or psychiatric disorders, other than stroke, that could interfere with upper limb motor or sensory recovery.\n* Modified Ashworth scale score ≥ 3 of the affected upper extremity.\n* Patients who are not able to sit with or without support.\n* Patients with severe apraxia, somatosensory problems.\n* Resting heart rate (\\\u003C 50 beats\u002Fmin).\n* Participants who are currently participating in another clinical trial or research study.","50 Years","75 Years",{"count":175,"type":21},50,[60],"Stroke is a leading cause of death and disability worldwide, resulting in significant physical and cognitive impairments. Arm weakness is most common after stroke and its treatment is recognized as an area of considerable need. The functional limitations and disabilities experienced by stroke survivors, particularly in the upper limb have a profound impact on their quality of life. Current treatment for arm weakness typically comprises intensive, task-specific and repetitive rehabilitative interventions. Transcutaneous auricular vagus nerve stimulation (tVNS) is a novel noninvasive treatment for stroke that directly stimulates the peripheral auricular branch of the vagus nerve. This study determines the effects of Vagus Nerve Stimulation and Modified Constraint Induced Movement Therapy on Motor Function, Cognition, and Quality of life in chronic stroke patients.\n\nThis randomized clinical trial will be conducted at IIMCT Railway General Hospital and Al-firdous physiotherapy clinic over a duration of six months. The sample size will consist of 50 participants. Participants which meet the inclusion criteria will be taken through non-probability convenience sampling technique, which will further be randomized through online randomization tool. 25 Participants will be assigned to Group A receiving tVNS and mCIMT with routine physical therapy and 25 to Group B receiving mCIMT with routine physical therapy . Data will be collected using various assessment tools, including Fugl-Meyer Assessment-UE (FM-UE), and Nine-hole peg test (NHPT) to assess Motor function. Stroke Impact Scale (SIS) to assess QOL, Montreal cognitive assessment (MoCA) to assess cognition, and Modified Ashworth scale to assess spasticity. All participants will receive intervention 3 days a week on alternative days for 8 weeks. Pre-intervention assessments will be conducted for both groups. The effects of the interventions will be measured at pre-treatment, 4th week, and post-intervention. Data analysis will be performed by using SPSS 26 software.\n\nKey words: Modified Constraint Induced movement Therapy, Motor function, Rehabilitation, Stroke, Transcutaneous Vagus nerve stimulation, Upper extremity.",[31,27],[180,181,182,183],"Vagus Nerve Stimulation","Motor Function","Modified Constraint Induced Movement Therapy","Upper Limb Function","2025-12-08",{"date":186,"type":41},"2025-12-09",{"date":188,"type":41},"2025-11-25",{"date":190,"type":21},"2026-05-05",{"name":192,"class":74},"Riphah International University",2,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":203,"conditions":204,"keywords":207,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":75},"100603663","use-of-physical-therapy-outcome-measures-to-predict-discharge-destination-in-people-with-stroke-from-acute-care-hospital-100603663","NCT07139444","Use of Physical Therapy Outcome Measures to Predict Discharge Destination in People With Stroke From Acute Care Hospital","Inclusion Criteria:\n\n1. Individuals who have a confirmed diagnosis of a first acute, single or multiple infarct, ischemic or hemorrhagic in nature by imaging.\n2. Individuals who are 18 years of age or older.\n3. Individuals must be non-institutionalized prior to hospital admission.\n4. Individuals whose primary spoken and written language is English.\n5. Individuals who are referred for physical therapy in acute care.\n\nExclusion Criteria:\n\n1. Individuals who are non-ambulatory prior to hospital admission.\n2. Individuals having a diagnosis of secondary major trauma or subarachnoid hemorrhage.\n3. Individuals with any comorbidity that prevents him\u002Fher from completing the tests such as a previous neurological injury or recent orthopedic diagnoses.","100 Years",{"count":202,"type":21},250,"Physical therapy assessments assist in discharge planning along with demographic and social factors for patients with stroke in acute care. Understanding where a patient can be discharged to, based on the patient's functional status post stroke is important to be able to use resources effectively, decrease length of stay, and facilitate early initiation of rehabilitation services if needed. Standardized outcome measures can help quantify functional deficits and the scores on the standardized outcome measures can in turn guide the discharge planning process. The Activity Measure for Post Acute Care \"6-Clicks\" (AM-PAC \"6-Clicks\") has been used in the acute care setting to guide discharge planning. Based on its cutoff scores, it also can assist in predicting discharge destination. The Mobility Scale for Acute Stroke (MSAS) has been used to determine discharge to home versus not home in patients with stroke. Understanding the validity of the MSAS in comparison with the Postural Assessment Scale for Stroke (PASS) and the AM-PAC \"6-Clicks\" can be beneficial as the MSAS is a stroke specific outcome measure which is mainly used in acute care and is easy to administer. It can be administered in a short duration and consists of mobility and balance assessments which can help determine functional deficits.",[205,27,31,206],"Stroke, Acute","Stroke Hemorrhagic",[118,208,209,210,211,212],"PASS","AM-PAC \"6-Clicks\"","MSAS","acute care hospital","physical therapy outcome measures","NOT_YET_RECRUITING","2025-08-17",{"date":216,"type":41},"2025-08-24",{"date":218,"type":21},"2025-09",{"date":220,"type":21},"2026-03",{"name":222,"class":74},"New York Presbyterian Brooklyn Methodist Hospital",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":231,"targetDuration":233,"studyType":22,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":75},"100064115","database-for-stroke-in-infants-and-children-the-international-pediatric-stroke-study-100064115","NCT00084292","Database for Stroke in Infants and Children: the International Pediatric Stroke Study","International Pediatric Stroke Study","IPSS","Inclusion Criteria:\n\nThis registry will include all children from birth to 18 years of age who are diagnosed with stroke or a condition\u002Fdisease (as defined below) that put them at high risk of stroke after Jan 1,2003 at one of the IPSS participating sites.\n\nThis registry will include children diagnosed with below stroke types:\n\n* Arterial Ischemic Stroke (AIS),\n* Cerebral Sinovenous Thrombosis (CSVT),\n* AIS and CSVT\n* Presume Preinatal Ischemic Stroke (PPIS)\n* Children diagnosed with hemorrhagic stroke\n\nChildren at high risk of stroke include:\n\n* Those diagnosed with arteriopathy, arteritis\u002Fvasculitis, moyamoya, dissection, sickle cell related infarcts).\n* Brain arteriovenous malformations\n\nExclusion Criteria:\n\n* Premature children diagnosed with AIS.\n* Premature children diagnosed with PPIS\n* Children diagnosed with TIA (Transient Ischemic Attack)\n* Brain hemorrhage secondary to trauma\n* Refusal to provide consent for participation",{"count":232,"type":21},12000,"12 Months","The International Pediatric Stroke Study (IPSS) was established in 2003 as a multi-center, multi-national clinical research registry. Over the years, it has grown to become a highly successful study vehicle for pediatric stroke research across over 100 institutions worldwide. Today, The IPSS continues to serve as the global clinical data and imaging core for multi-disciplinary pediatric experts who perform international collaborative research to better understand, prevent, and improve outcomes in pediatric stroke. The robust dataset and cohesive network enable high caliber and ground-breaking research in the field.\n\nParticipating sites enroll neonates or children who have had an ischemic or hemorrhagic stroke, or may be at high risk of having a stroke. Participants have their medical and research records reviewed for information about their stroke and abstracted into a secure electronic database called REDCap, which is hosted at SickKids in Toronto Canada. The IPSS also provides an attractive imaging platform (through the Stroke Imaging Lab for Children, SILC, housed at SickKids) for sites to share clinically acquired brain images that will complement the clinical dataset. The clinical and imaging datasets will improve our understanding of the processes underlying plasticity and recovery in childhood stroke.",[27,236],"Focal Infarct",[238,239,240,241,242,243,244,245,246,247,248,249,250,251],"Ischemia","Pediatric","Etiology","Treatment","Outcome","Childhood Stroke","Pediatric Stroke","Ischemic Stroke","Spastic Hemiplegia","Hemiplegic cerebral palsy","Neonatal Stroke","Neuroimaging","Arteriopathy","Hemorrhagic","2025-05-12",{"date":254,"type":41},"2025-05-15",{"date":256,"type":41},"2003-01",{"date":258,"type":21},"2030-12",{"name":260,"class":74},"The Hospital for Sick Children",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":58,"phases":270,"briefSummary":271,"conditions":272,"keywords":279,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":298},"100524306","effects-of-atalante-exoskeleton-on-gait-recovery-in-non--or-poorly-ambulatory-patients-with-hemiparesis-in-the-acutesubacute-phase-month-1-to-4-100524306","NCT06107010","Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute\u002FSubacute Phase (Month 1 to 4)","EarlyExo","Inclusion Criteria:\n\n* \\>18 years old\n* First clinically significant disability due to stroke\n* Hemiparesis in acute-subacute phase (1 to 4 months since lesion) due to a stroke\n* Functional Ambulation Category score (FAC) \\\u003C2\n* Patient with health insurance\n* Informed and willing to sign an informed consent form approved by the Ethics Committee. For clarity, if a motor impairment prevents the subject from signing by himself, he\u002Fshe can still be included if the signature can be done by an impartial witness.\n\nExclusion Criteria:\n\n* Muscle overactivity in hip adductors, hamstrings, quadriceps and plantar flexors, which interferes with exoskeleton use, based on clinician investigator's opinion\n* Recent fracture (\\\u003C 3 months) or any therapy inducing secondary osteoporosis\n* Excessive joint mechanical pain in the lower limbs based on clinician investigator's opinion\n* Pressure sore grade I or more over contact zones with Atalante system, according to the International Pressure Ulcer Classification System NPUAP - EPUA\n* Medical contra-indication to medium intensity physical strain\n* Orthostatic hypotension (loss of \\> 20 mmHg systolic BP after 3 minutes in standing position)\n* Uncontrolled seizures\n* Morphological contra-indications to the use of Atalante (as per user's manual)\n* Pregnant woman\n* Adults who lack the capacity to provide informed consent, and all those persons deprived of their liberty in prisons or other places of detention\n* Concurrent participation in another interventional trial",{"count":269,"type":21},66,[60],"The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.\n\nThis clinical investigation is designed to test the hypothesis that early and intense introduction of walking sessions assisted by the Atalante exoskeleton, in a sample of hemiparetic patients with still non or poor ambulatory capacities (FAC 0 or 1) between one- and four-months post stroke, would result in a better recovery of functional walking compared to a control group only receiving conventional therapy. Improved recovery will be measured through the proportion of patients reaching a FAC score of 4 or higher at the end of the intervention period. The tested hypothesis is that this proportion will be higher in the Exo group.\n\nThe duration of the intervention period in both groups is 6 weeks.\n\n* For the Exo group: 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy.\n* For the Control group: 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).\n\nThe study will include 66 patients (33 in each arm) and takes place in two French centers, two German centers and one Spanish center.",[205,273,274,206,275,27,276,277,278],"Stroke, Ischemic","Stroke, Subacute","Cerebrovascular Disorders","Hemiparesis","Hemiparesis;Poststroke\u002FCVA","Hemiparesis\u002FHemiplegia (One Sided Weakness\u002FParalysis)",[280,281,282,283,31,284,285,286,287],"Robotics","Rehabilitation","Powered Exoskeleton","Walking recovery","Acute stroke","Subacute stroke","Functional Ambulation Category","Randomized controlled study","2025-01-30",{"date":290,"type":41},"2025-02-04",{"date":292,"type":41},"2023-06-12",{"date":294,"type":21},"2026-02-28",{"name":296,"class":297},"Wandercraft","INDUSTRY",5,{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":306,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":58,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":75},"100441180","videographic-feedback-and-walk-rehabilitation-in-post-cerebrovascular-accident-100441180","NCT05024981","Videographic Feedback and Walk Rehabilitation in Post-Cerebrovascular Accident","CoDévi","Inclusion Criteria:\n\n* Hospitalization for a first episode of Cerebrovascular Accident less than six months old, or nth stroke less than six months old, with no previous sequelae;\n* Able to walk at least 10m without stopping, with or without technical assistance, but without human assistance, under supervision;\n\nExclusion Criteria:\n\n* Palliative or life-threatening situation;\n* A patient whose guardian or trustee is not readily available to provide information about the patient\n* Neuro-cognitive disorder that prevents understanding of instructions, as determined by the clinician;\n* Severe speech or language disorder that prevents the protocol from being carried out correctly;\n* Hemineglect;\n* Any previously known pathology altering the gait pattern, at the clinician's discretion (recent neurological, traumatological or orthopaedic pathologies, etc.);\n* Visual disorder preventing viewing of the video;\n* Hearing disorder preventing comprehension.","70 Years",{"count":308,"type":21},64,[60],"Cerebrovascular Accident affects the majority of the elderly population and its frequency is constantly increasing. The resulting deficits are numerous and lead in particular to an alteration in the quality of walking and autonomy. Numerous rehabilitation techniques have been described. In practice, correction instructions are often given by the therapist while the motor activity is being performed. Walking is a complex activity, as is the processing of dual-task information in elderly stroke patients. It therefore appears interesting to separate the time of motor realization and that of correction instructions. Investigators therefore propose firstly to film the patient during the performance of a walking activity and then, secondly, to analyse the video with the patient, which thus represents a source of delayed feedback. The main objective of the study is to observe the effects of this practice on walking speed. Investigators are comparing two groups of patients: the control group receiving conventional rehabilitation and the experimental group receiving conventional rehabilitation plus sessions with the video tool. They expect to observe a greater improvement in walking speed in the experimental group.",[27],"2024-12-06",{"date":314,"type":41},"2024-12-11",{"date":316,"type":41},"2022-03-04",{"date":318,"type":21},"2027-01-04",{"name":320,"class":74},"Centre Hospitalier Universitaire de Nice",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":58,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":338,"leadSponsor":339,"locationsCount":75},"100554355","cognitive-somatosensory-motor-training-to-improve-arm-and-hand-function-after-stroke-icosmo-100554355","NCT06498011","COgnitive-somatoSensory-MOtor Training to Improve Arm and Hand Function After Stroke (iCOSMO)","Comparing the Effect of a Graded Repetitive Arm Supplementary Home-based Exercise Programme With COgnitive-somatoSensory-MOtor Training to Improve Arm and Hand Function After Stroke (iCOSMO)","iCOSMO","Inclusion Criteria:\n\n* Clinical diagnosis of stroke\n* Must be more than 6 months post-stroke\n* Must be above 18 years old\n* Must have some motor and\u002For somatosensory deficits in the upper limbs\n\nExclusion Criteria:\n\n* A prior history of central nervous system dysfunction other than stroke\n* Upper limb deficits resulting from non-stroke pathology\n* Inability to cooperate, follow instructions or provide consent",{"count":330,"type":21},40,[60],"The iCOSMO study investigates the feasibility and beneficial effects of an intervention combining sensation, motor and cognition to improve arm and hand function after chronic stroke.",[31,334,27],"CVA","2024-12-05",{"date":314,"type":41},{"date":160,"type":41},{"date":71,"type":21},{"name":340,"class":74},"University Health Network, Toronto",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":58,"phases":350,"briefSummary":351,"conditions":352,"keywords":357,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":75},"100557504","adherence-to-long-term-exoskeleton-rehabilitation-to-treat-lower-limb-weakness-and--or-deficiencies-in-adult-population-100557504","NCT06538974","Adherence to Long-term Exoskeleton Rehabilitation to Treat Lower Limb Weakness and \u002F or Deficiencies in Adult Population","ALERT","Inclusion Criteria:\n\n* Patient suffering from lower limb weaknesses and \u002F or deficiencies regardless of the cause\n* Adult patient ≥18 years old\n* Patient able to read and write in French and who have signed an informed consent form\n* Patient affiliated to a social security system.\n\nExclusion Criteria:\n\n* Individual with severe spasticity of adductor muscles, hamstring, quadriceps and triceps surae. Severe spasticity is defined by a score of 4 on the modified Ashworth scale\n* Pregnant woman\n* Individual with history of osteoporotic fracture and \u002F or pathology or treatment causing secondary osteoporosis\n* Pressure Ulcer of Grade I or higher according to the NPUAP International Pressure Ulcer Classification System- EPUAP, in areas of contact with the Atalante X system\n* Severe aphasia limiting ability to express needs or to fulfil questionnaires, at the discretion of the physician.\n* Patient with a cardiac or respiratory contraindication to physical exertion, at discretion of the physician\n* Patient unable to deliver his\u002Fher consent\n* Patient under legal protection\n* Patient participating at the same time in another study\n* Patients with morphological contraindications to the use of the Atalante X exoskeleton (as per user's manual) with exceptions as follows: knee flessum of 20° authorized if sensibility is present; equinus of the ankle of 20° allowed regardless of presence or absence of sensibility, hip flessum of 20° allowed regardless of presence or absence of sensibility.",{"count":349,"type":21},100,[60],"In 2019, approximately 2.4 billion people worldwide required rehabilitation for various health pathologies, a 63% increase since 1990. It has been suggested that current rehabilitation frameworks (inpatient, outpatient, and community-based) are insufficient to meet local population needs due to issues like long waiting times, lack of facilities, prioritization, funding, and accessibility.Patients with lower limb weaknesses, resulting from various conditions (for example stroke, traumatic brain injury, spinal cord injury and others) require long-term management and motivation for engagement, which are crucial for functional outcomes. This highlights the need for sustainable gait and balance rehabilitation.\n\nNew technologies like exoskeletons have shown promising results in short-term inpatient programs, improving gait, balance, and quality of life, however, long-term follow-up data are still needed.\n\nThe present clinical investigation is a national, prospective, open-label interventional trial, proposing a 12-month outpatient rehabilitation program with the Atalante X exoskeleton to treat lower limb weakness and\u002For impairments in 100 participants. The rehabilitation program consists of at least one exoskeleton rehabilitation session per week. At the end of the first-year experimental phase, participants can continue for an additional year in the voluntary phase. The program aims to explore the potential long-term effects of supervised robotic rehabilitation on motor, cognitive, bowel, bladder functions, quality of life, and well-being. Assessments are conducted at baseline, after 4 and 12 months of exoskeleton rehabilitation, and at 16 and 24 months for participants in the voluntary phase.",[353,354,355,90,356,27],"Motor Disorders","Gait Disorders, Neurologic","Neurodegenerative Diseases","Weakness, Muscle",[358,359,360,361,281],"Hands-free Exoskeleton","Atalante X","Gait","Balance","2024-07-31",{"date":364,"type":41},"2024-08-06",{"date":366,"type":41},"2023-02-16",{"date":368,"type":21},"2027-07-02",{"name":296,"class":297},{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":58,"phases":380,"briefSummary":381,"conditions":382,"keywords":393,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":402,"locationsCount":75},"100420789","neurorehabilitation-through-hippotherapy-of-a-brain-stroke-100420789","NCT04759326","Neurorehabilitation Through Hippotherapy of a Brain Stroke","Neurorehabilitation Through Hippotherapy on Neurofunctional Sequels of Brain Stroke: (i) Effect on Patient's Functional Independence, Sensorimotor and Cognitive Capacities and Quality of Life (ii) Effect on Caregivers' Quality of Life","HippoPostCVA","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Ischemic or haemorrhagic stroke according to ICD 10 I61-I69 (30)\n* Inclusion \\> 3 months post-stroke\n* Deficit still existing (Rankin score ≥ 3 and ≤ 4 at inclusion)\n* Existing declaration of informed consent\n* Affiliation of the patient to a social security scheme\n* Minimal abduction of the hip of 25 degrees bilateral with no history of hip dislocation and\u002For dysplasia\n* Certificate of non-contraindication issued by the referring physician\n\nExclusion Criteria:\n\n* Major cognitive impairment affecting comprehension (Mini Mental State Examination test \\\u003C 24 points)\n* Global or sensory aphasia\n* Neurological or psychiatric co-morbidity (other than mild-to-moderate post-stroke depression)\n* Evidence of an uncontrolled seizure disorder\n* Substance abuse\n* History of uncontrolled pain\n* History of allergic reactions to dust and\u002For horsehair, or severe asthma\n* Overweight (≥ 110 kg)\n* Contraindications to physical activity\n* Inability or medical contraindication to travel to the Equiphoria Institute by personal car or taxi\n* History of horse riding or hippotherapy care during the last 6 months\n* Pregnant or lactating women\n* Patients participating in other biomedical research or in a period of exclusion",{"count":379,"type":21},52,[60],"Cerebrovascular accident \\[CVA\\] (medical term for stroke) is a high burden worldwide disorder and the second leading cause of disability. As illustrated by the number of survivors that remain disabled after a CVA (2 out of 3 according to the US National Stroke Association), recovery is limited, and novel neurorehabilitation approaches are urgently needed. Hippotherapy is an emerging specialized rehabilitation approach, performed by accredited health professionals on a specially trained horse via its movement. A body of scientific evidence has gradually emerged in recent years, showing robust benefits of hippotherapy in various massive neurological disabling conditions including brain stroke.\n\nThe aim of the study is to analyze the effect of a hippotherapy program of several cycles delivered during 22 weeks in total, on the functional and global evolution of post-stroke patients (with a score of Rankin ≥ 3 at inclusion) during the outpatient rehabilitation phase. A second purpose is to measure the impact of the intervention on the quality of life of their close caregivers.\n\nA prospective clinical trial on the effectiveness of hippotherapy versus conventional outpatient rehabilitation alone will be carried out. The 22-weeks program includes three cycles of hippotherapy as follows: an initial 2-weeks cycle, an intermediate 1-week cycle and a final 1-week cycle. One-hour daily sessions will be conducted during each cycle exclusive additional rehabilitation care. After each cycle, the patients will have a 9-weeks rest period where they will continue their conventional therapy. A battery of clinical tests will measure both functional and psychological outcome. The primary end point will be the functional independence of the patient. The secondary end points will consider the patient's sensorimotor and cognitive function, the severity of stroke and the quality of life, as well as the caregivers' burden and quality of life.\n\nProgram evaluation is important in neurorehabilitation to ensure that patients are achieving meaningful outcomes from the care. A primary question is how do stroke patients clinically evolve after being discharged from the hospital and how stable is the achieved rehabilitation outcome. Hippotherapy optimizes brain plasticity and has a strong impact on the global rehabilitation process and functional outcome of these patients. A remaining question concerns the improvement of the caregivers' quality of life.",[27,383,384,385,386,387,388,389,390,391,392],"Neurorehabilitation","Neuroplasticity","Hippotherapy","Silent Neurofunctional Barriers","Functional Deficit","Cognitive Deficit","Psychological Trauma","Autonomy","Quality of Life","Caregiver Burnout",[394,395,396],"NeuroRehabilitation through hippotherapy","Brain plasticity","Functional recovery","2024-07-30",{"date":362,"type":41},{"date":400,"type":41},"2022-04-27",{"date":220,"type":21},{"name":403,"class":74},"Alliance Equiphoria",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":58,"phases":415,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":75},"100556824","promote-awareness-of-the-driving-abilities-of-post-stroke-patients-100556824","NCT06530134","Promote Awareness of the Driving Abilities of Post-stroke Patients.","Promote Awareness of the Driving Abilities of Post-stroke Patients: Interest of On-board Cameras and Self-assessment Questionnaires During a Driving Situation.","AUTOCAM-AVC","Inclusion Criteria:\n\n* Stroke (ischemic and \u002F or hemorrhagic) between 1 month and 6 months\n* Holder of a driving license for more than 3 years\n* No resumption of driving\n* MoCA score ≥ 10\n* Affiliation to a social security scheme or beneficiary of such a scheme\n* Having signed a free, informed and written consent\n* Medically stable\n\nExclusion Criteria:\n\n* Aphasia with severe comprehension disturbances, severe hemineglect, unstable epilepsy, severe visual disturbances (binocular vision \\\u003C6\u002F10, visual field \\\u003C120 ° in binocular, \\\u003C50 ° to the right and to the left beyond the central point, \\\u003C30 ° vertically.\n* History of neurological disease responsible for cognitive impairment\n* Need for vehicle modifications except automatic gearbox\n* Subject being in a period of exclusion from another protocol\n* Insufficient command of the French language\n* Protected adults (curators)\n* Pregnancy declared\n* Being unable to issue their consent","85 Years",{"count":414,"type":21},70,[60],"Patients with cerebrovascular accident (CVA) may present with a deficit of awareness of the disorders which results in a lack of correct self-estimation of their own abilities and difficulties in terms of both cognition and driving. It is therefore important to develop tools to help professionals take this deficit into account in their driving assessments and also to help patients better identify their real abilities.\n\nThis research project thus proposes a protocol making it possible to promote decision-making whether or not to resume driving by multidisciplinary teams.\n\nThe main objective is to determine to what extent video feedback promotes awareness of the ability to manage post-stroke patients, compared to a group of control patients receiving the usual recommendations.",[27],[419],"post-stroke","2024-07-27",{"date":362,"type":41},{"date":423,"type":41},"2021-10-12",{"date":425,"type":21},"2024-11",{"name":427,"class":74},"Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape",{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":436,"sex":16,"minAge":17,"maxAge":437,"enrollmentInfo":438,"targetDuration":440,"studyType":22,"phases":4,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":75},"100544672","ipsc-biobank-of-biomarkers-diversity-in-cardiovascular-disease-100544672","NCT06371937","iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease","Blood Biomarkers From Ethnically Diverse Cardiovascular Patients","INFERENCE","Inclusion Criteria:\n\n* Adult (18 to 80 years of age)\n* Cardiovascular Disease (CVD)\n* Cerebrovascular Disease (CBD)\n* Peripheral Vascular Disease (PVD)\n* Inherited Arrhythmias\n* Cardiomyopathies\n* Congenital Heart Disease (CHD)\n* Aortopathy\n* Hypertension\n* Cardiometabolic Disease (CMD)\n\nExclusion Criteria:\n\n* Younger than 18 years of age.\n* Patients not able to provide consent.",true,"80 Years",{"count":439,"type":21},200,"10 Years","The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.",[443,444,445,446,27,447,448],"Cardiovascular Diseases","Arrythmia","Cardiomyopathies","Heart Failure","Congenital Heart Disease","Cardiometabolic Syndrome","2024-05-28",{"date":451,"type":41},"2024-05-29",{"date":453,"type":41},"2024-05-01",{"date":455,"type":21},"2033-06-30",{"name":457,"class":74},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":11,"sex":16,"minAge":464,"maxAge":412,"enrollmentInfo":465,"targetDuration":4,"studyType":58,"phases":467,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":75},"100457567","novel-brain-neurotechnology-for-optimizing-precision-mirror-therapy-in-stroke-100457567","NCT05238272","Novel Brain Neurotechnology for Optimizing Precision Mirror Therapy in Stroke","Inclusion Criteria:\n\n1. ≥ 3 months onset from a first-ever unilateral stroke;\n2. an initial FMA scores between 18 to 56, indicating moderate to mild upper extremity motor impairment (Thielman, Kaminski, \\& Gentile, 2008);\n3. age between 35 to 85;\n4. no excessive spasticity in any of the joints of the affected arm (shoulder, elbow, wrist and fingers);\n5. ability to follow instructions and perform tasks (Mini Mental State Examination scores ≥24);\n6. no participation in any neurorehabilitation experiments or drug clinical trials and\n7. willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. contradiction to tRNS including a history of epilepsy, pregnant, having pacemakers and metallic implants in the neck and heads (Rossi, Hallett, Rossini, Pascual-Leone, \\& Safety of, 2009);\n2. History of drug or alcohol abuse(Rossi et al., 2009);\n3. concomitant neurological conditions such as dementia, Parkinson's disease, brain tumor, brain injury and other brain diseases (such as intracranial hypertension or cerebral edema);\n4. Botulinum toxin injections 3 months before enrollment\n5. have unstable cardiovascular status such as uncontrolled hypertension or New York Heart Association (NYHA) Class III\u002FIV heart failure or are not suitable for receiving tRNS by the physician's assessments.","35 Years",{"count":466,"type":21},128,[60],"The primary aim of this project will be to determine the effects of the tRNS-augmented unilateral and bilateral MT, and their effects relative to the control interventions (sham tRNS with unilateral or bilateral MT) on restoring health outcomes including motor function, daily function, quality of life and self-efficacy, and motor control strategy as well as brain activities (electroencephalography, EEG) in stroke patients.",[27],[471,118],"Mirror therapy","2022-02-11",{"date":474,"type":41},"2022-02-14",{"date":476,"type":21},"2022-03-01",{"date":478,"type":21},"2026-12-31",{"name":480,"class":74},"Chang Gung Memorial Hospital"]